FindTrial
Sign In

Radiotherapy (SBRT) and/or surgery (metastasectomy)

OTHER2 trials

Sponsors

Universitaire Ziekenhuizen KU Leuven

Conditions

Castration-resistant Prostate CancerHormone Sensitive Prostate CancerMetastatic CancerOligometastasisOligometastatic DiseaseProstate CancerProstate Cancer MetastaticProstate Cancer Recurrent

Phase 3

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
RecruitingNCT05352178
Universitaire Ziekenhuizen KU LeuvenHormone Sensitive Prostate Cancer, Metastatic Cancer, Oligometastasis +4
Start: 2022-04-20End: 2032-04-25Target: 873Updated: 2024-07-03

Unknown Phase

Metastasis-directed Therapy in Castration-refractory Prostate Cancer
Active, not recruitingNCT04222634
Universitaire Ziekenhuizen KU LeuvenCastration-resistant Prostate Cancer
Start: 2019-12-27End: 2030-01-01Target: 18Updated: 2023-12-07

Related Papers

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
2022-12-129 citations
Metastasis-Directed Therapy for Oligoprogressive Castration-Resistant Prostate Cancer - Preliminary Results of the Prospective, Single-Arm MEDCARE Trial.
2021-11-016 citations
Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial.
2020-05-2411 citations